A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Launched by AMRYT PHARMA · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a topical gel called Filsuvez in patients with a condition known as epidermolysis bullosa (EB), which makes their skin very fragile and prone to blisters. Patients with two specific types of EB—dystrophic EB and junctional EB—are being recruited for this study. The main goal is to find out if using Filsuvez helps reduce the risk of developing skin cancers, which these patients are more likely to get. Participants will receive standard care, which may include Filsuvez or other treatments, and they will be monitored for up to five years.

To be eligible for this trial, individuals must have a confirmed diagnosis of either dystrophic EB or junctional EB. There are no specific exclusions based on age or gender, so anyone who meets the diagnosis criteria can participate. Throughout the study, participants can expect regular check-ups to track their health and skin condition, helping researchers understand how Filsuvez impacts their overall risk of skin malignancies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a confirmed diagnosis of dystrophic EB or junctional EB
• Exclusion Criteria:
• • None